Financials data is unavailable for this security.
View more
Year on year Syndax Pharmaceuticals Inc 's net income fell 40.19% from a loss of 149.34m to a larger loss of 209.36m despite flat revenues.
Gross margin | -- |
---|---|
Net profit margin | -1,856.64% |
Operating margin | -2,007.58% |
Return on assets | -72.01% |
---|---|
Return on equity | -81.88% |
Return on investment | -81.78% |
More ▼
Cash flow in USDView more
In 2023, Syndax Pharmaceuticals Inc increased its cash reserves by 296.95%, or 221.14m. Cash Flow from Financing totalled 264.13m or -- of revenues. In addition the company used 160.60m for operations while cash from investing totalled 117.61m.
Cash flow per share | -3.62 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.28 |
---|---|
Tangible book value per share | 4.28 |
More ▼
Balance sheet in USDView more
Current ratio | 6.99 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00003 |
---|---|
Total debt/total capital | 0.00003 |
More ▼